However, several considerations need to be kept in mind in the interpretation of these data
In the LEAVO study, the comparison between aflibercept and bevacizumab was not a primary outcome but only a post-hoc analysis of the study. For this reason, the noninferior results of bevacizumab in comparison to aflibercept, in our opinion, are inconclusive. Taking together this information, the LEAVO study failed to demonstrate a noninferiority of bevacizumab in comparison to ranibizumab and aflibercept.
Another important point regards the safety and the efficacy of the bevacizumab compounding process. Indeed, during the procedures used by pharmacies to compound bevacizumab, the drug could be affected by microbial contamination causing higher levels of infectious endophthalmitis [4] . Furthermore, higher levels of sterile endophthalmitis caused by excess silicone oil residue and particulates were reported [5, 6] . This could be due to significant higher variability in the protein concentration of bevacizumab compounded from pharmacies in comparison to the drug acquired directly from the manufacturer [7] . The compounding process of bevacizumab causes not only possible microbial contamination and higher protein concentration variability but also a significant lowering and variability of the drug concentration in comparison to the Genentech sample [7] . This variability may have important clinical and ethical implications for ophthalmologists and patients. Despite these findings, to date the majority of clinical trials reported no higher levels of endophthalmitis using bevacizumab in comparison to ranibizumab and aflibercept. However, the bevacizumab used in these series was prepared from compounding pharmacies that may not have been representative of the standard real-life process. Furthermore, no clinical trials were designed to analyse the safety of the drugs, and then the sample size is likely underpowered to detect differences in the endophthalmitis rate.
Great caution should be taken in the comparison between clinical trials and real-life data. For instance, clinical trials have a high rate of treatment adherence and the optimized interval between injections in comparison to the adherence of patients and the number of injections for a year in the clinical practice [2, 8] . In real-life, Italian patients received a lower number of injections in comparison with other European countries in the treatment of age-related macular degeneration [8] . This difference reflects the greater visual acuity decline in Italian patients from baseline to year 2. Real-life studies comparing different anti-VEGF monotherapies with a long term follow-up in CRVO patients should be performed in order to evaluate the outcomes in the clinical practice.
In conclusion, previous studies comparing anti-VEGF did not clarify whether bevacizumab is inferior in terms of vision outcome to ranibizumab and aflibercept with a long-term follow-up. Real-life studies are recommended to evaluate the adherence to the therapy, the difference in visual acuity outcomes between anti-VEGF drugs, and the clinical effects of the bevacizumab compounding process.
